Heron Therapeutics (HRTX) Competitors $1.40 +0.08 (+6.06%) Closing price 04:00 PM EasternExtended Trading$1.44 +0.04 (+2.79%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HRTX vs. BGM, OCS, AVBP, NRIX, GYRE, IMTX, PROK, MNMD, PHAT, and AMLXShould you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include BGM Group (BGM), Oculis (OCS), ArriVent BioPharma (AVBP), Nurix Therapeutics (NRIX), Gyre Therapeutics (GYRE), Immatics (IMTX), ProKidney (PROK), Mind Medicine (MindMed) (MNMD), Phathom Pharmaceuticals (PHAT), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. Heron Therapeutics vs. Its Competitors BGM Group Oculis ArriVent BioPharma Nurix Therapeutics Gyre Therapeutics Immatics ProKidney Mind Medicine (MindMed) Phathom Pharmaceuticals Amylyx Pharmaceuticals Heron Therapeutics (NASDAQ:HRTX) and BGM Group (NASDAQ:BGM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability. Do insiders & institutionals believe in HRTX or BGM? 80.0% of Heron Therapeutics shares are held by institutional investors. 5.9% of Heron Therapeutics shares are held by insiders. Comparatively, 58.7% of BGM Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, HRTX or BGM? Heron Therapeutics has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, BGM Group has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Does the media prefer HRTX or BGM? In the previous week, Heron Therapeutics had 2 more articles in the media than BGM Group. MarketBeat recorded 2 mentions for Heron Therapeutics and 0 mentions for BGM Group. Heron Therapeutics' average media sentiment score of 1.28 beat BGM Group's score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Heron Therapeutics Positive BGM Group Neutral Do analysts prefer HRTX or BGM? Heron Therapeutics presently has a consensus price target of $4.50, indicating a potential upside of 221.43%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than BGM Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heron Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33BGM Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher earnings & valuation, HRTX or BGM? BGM Group has lower revenue, but higher earnings than Heron Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHeron Therapeutics$144.29M1.49-$13.58M-$0.02-70.00BGM Group$25.10M30.27-$1.44MN/AN/A Is HRTX or BGM more profitable? BGM Group has a net margin of 0.00% compared to Heron Therapeutics' net margin of -0.62%. Company Net Margins Return on Equity Return on Assets Heron Therapeutics-0.62% N/A -0.40% BGM Group N/A N/A N/A SummaryHeron Therapeutics beats BGM Group on 7 of the 13 factors compared between the two stocks. Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRTX vs. The Competition Export to ExcelMetricHeron TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$202.35M$2.51B$5.76B$9.59BDividend YieldN/A1.67%4.41%4.09%P/E Ratio-70.005.3022.4021.92Price / Sales1.49752.08472.14121.31Price / CashN/A180.4637.7358.48Price / Book-7.785.939.536.61Net Income-$13.58M$31.83M$3.26B$265.56M7 Day Performance5.26%1.80%2.11%1.98%1 Month Performance-26.32%4.36%5.12%1.33%1 Year Performance-25.13%11.44%31.25%21.15% Heron Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRTXHeron Therapeutics4.2427 of 5 stars$1.40+6.1%$4.50+221.4%-33.3%$202.35M$144.29M-70.00300Positive NewsBGMBGM GroupN/A$8.15+7.7%N/A+28.5%$792.34M$25.10M0.00298OCSOculis3.2721 of 5 stars$18.06+0.9%$35.33+95.6%+49.1%$788.54MN/A-6.842News CoverageEarnings ReportAnalyst ForecastAVBPArriVent BioPharma2.5211 of 5 stars$19.24-1.5%$39.14+103.4%-16.9%$780.57MN/A-4.7940NRIXNurix Therapeutics2.665 of 5 stars$10.20-3.6%$28.87+183.0%-59.6%$779.79M$54.55M-3.91300High Trading VolumeGYREGyre Therapeutics0.1195 of 5 stars$7.85-3.6%N/A-36.9%$756.03M$105.76M785.7940Gap UpIMTXImmatics1.9651 of 5 stars$6.21-1.9%$14.67+136.2%-51.2%$754.83M$168.65M-9.55260PROKProKidney3.765 of 5 stars$2.54+7.6%$6.25+146.1%-2.9%$743.46M$80K-4.463News CoverageShort Interest ↓MNMDMind Medicine (MindMed)2.8984 of 5 stars$9.75+1.5%$24.71+153.5%+53.2%$741.88MN/A-6.3740Positive NewsPHATPhathom Pharmaceuticals2.682 of 5 stars$10.10-1.4%$17.50+73.3%-15.6%$716.49M$55.25M-2.14110AMLXAmylyx Pharmaceuticals3.5093 of 5 stars$7.99-0.1%$11.75+47.1%+273.0%$712.47M$87.37M-3.20200News CoveragePositive News Related Companies and Tools Related Companies BGM Group Competitors Oculis Competitors ArriVent BioPharma Competitors Nurix Therapeutics Competitors Gyre Therapeutics Competitors Immatics Competitors ProKidney Competitors Mind Medicine (MindMed) Competitors Phathom Pharmaceuticals Competitors Amylyx Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HRTX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access